NCT00347958View on ClinicalTrials.gov

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

545

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

October 31, 2008

Conditions
TetanusDiphtheriaPertussis
Interventions
BIOLOGICAL

Tetanus-diphtheria-acellular pertussis (Tdap) vaccine

0.5mL, Intramuscular (IM)

Trial Locations (10)

15241

Pittsburgh

44118

University Heights

71111

Bossier City

72401

Jonesboro

V3C 4J2

Coquitlam

V3R-8P8

Surrey

R3E 3P4

Winnipeg

B3K-6R8

Halifax

G1E 7G9

Beauport

H3H LP3

Montreal

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00347958 - Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine | Biotech Hunter | Biotech Hunter